Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SGL5213 is an oral active and low-absorbable inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1)(hSGLT1 and hSGLT2 with IC50 values of 29 nM and 20 nM , respectively),and has potential to treat type 2 diabetes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | Inquiry | |
50 mg | 10-14 weeks | Inquiry | |
100 mg | 10-14 weeks | Inquiry |
Description | SGL5213 is an oral active and low-absorbable inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1)(hSGLT1 and hSGLT2 with IC50 values of 29 nM and 20 nM , respectively),and has potential to treat type 2 diabetes. |
Targets&IC50 | SGLT1/ SGLT2 (human):29nM/20 nM |
Molecular Weight | 669.85 |
Formula | C37H55N3O8 |
CAS No. | 1240305-17-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SGL5213 1240305-17-2 GPCR/G Protein SGLT SGL 5213 SGL-5213 inhibitor inhibit